Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension

International Journal of Cardiology

Volumn 96, Issue 2, 2004, Pages 265-271

  Rivera Otero, J Miguel ^a   Taléns Visconti, Raquel ^a   Salvador, Antonio ^b   Bertomeu, Vicente ^c   Miró, Vicente ^a   Jordán, Alejandro ^d   Sogorb, Francisco ^e   Cortés, Raquel ^a   Payá, Rafael ^f   Diago, Jose Luis ^g   Grau, Guillermo ^h  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c San Juan Hospital   (Spain)

^d Elche University Hospital   (Spain)

^e GENERAL HOSPITAL   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^g GENERAL HOSPITAL   (Spain)

^h Alcoy Hospital   (Spain)

Author keywords

Hypertension; Left ventricular hypertrophy; NT proBNP

Indexed keywords

PEPTIDE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSPNEA; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VOLUME; HEMOCONCENTRATION; HOSPITAL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE TISSUE PROTEINS; OBSERVER VARIATION; PEPTIDE FRAGMENTS; PROBABILITY; PROGNOSIS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 3242798989     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.07.019     Document Type: Article

References (42)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl. J. Med. 322:1990;1561-1566
2. Schillaci G., Verdecchia P., Porcellati C., Cuccurullo O., Cosco C., Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 35:2000;580-586
3. Devereux R.B., de Simone G., Ganau A., Koren M.J., Mensah G.A., Roman M.J. Left ventricular hypertrophy and hypertension. Clin. Exp. Hypertens. 15:1993;1025-1032
4. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann. Intern. Med. 114:1991;345-352
5. Devereux R.B., James G.D., Pickering T.G. What is normal blood pressure? Comparison of ambulatory pressure level and variability in patients with normal or abnormal left ventricular geometry. Am. J. Hypertens. 6:1993;211S-221S
6. Ganau A., Devereux R.B., Roman M.J., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J. Am. Coll. Cardiol. 19:1992;1550-1558
7. Basile J. Hypertension in the elderly: a review of the importance of systolic blood pressure elevation. J. Clin. Hypertens. (Greenwich). 4:2002;108-112. (119)
8. Zoccali C., Mallamaci F., Tripepi G. Hypertension as a cardiovascular risk factor in endstage renal failure. Curr. Hypertens. Rep. 4:2002;381-386
9. Mair J., Hammerer-Lercher A., Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin. Chem. Lab. Med. 39:2001;571-588
10. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature. 332:1988;78-81
11. Groenning B.A., Nilsson J.C., Sondergaard L., et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am. Heart J. 143:2002;923-929
12. Nishigaki K., Tomita M., Kagawa K., et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol. 28:1996;1234-1242
13. Hasegawa K., Fujiwara H., Doyama K., et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation. 88:1993;372-380
14. Yamamoto K., Burnett J.C. Jr., Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 28:1996;988-994
15. Davidson N.C., Naas A.A., Hanson J.K., Kennedy N.S., Coutie W.J., Struthers A.D. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am. J. Cardiol. 77:1996;828-831
16. Cho Y., Somer B.G., Amatya A. Natriuretic peptides and their therapeutic potential. Heart Dis. 1:1999;305-328
17. Remme W.J., Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22:2001;1527-1560
18. Cowie M.R., Mendez G.F. BNP and congestive heart failure. Prog. Cardiovasc. Dis. 44:2002;293-321
19. De Lemos J.A., Morrow D.A., Bentley J.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. New Engl. J. Med. 345:2001;1014-1021
20. Rivera M., Talens R., Garcia de Burgos F., et al. Hypertension and N-terminal pro-brain natriuretic peptide. Its importance in the diagnosis of heart failure. Circulation. 106:2002;2358
21. Pieske B., Herrmann-Lingen C., von Lewinski D., et al. NT-pro brain natriuretic peptide as marker for severity and prognosis of left ventricular dysfunction. Circulation. 106:2002;3371
22. Luchner A., Burnett J.C. Jr., Jougasaki M., et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J. Hypertens. 18:2000;1121-1128
23. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;995-1003
24. Dahlof B., et al. REGAAL Study Investigators. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J. Hypertens. 20:2002;1855-1864
25. Pries A.R., Secomb T.W. Structural adaptation of microvascular networks and development of hypertension. Microcirculation. 9:2002;305-314
26. Cosin J., Asin E., Marrugat J., et al. Prevalence of angina pectoris in Spain. PANES Study group. Eur. J. Epidemiol. 15:1999;323-330
27. Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch. Intern. Med. 157:1997;2413-2446
28. Karl J., Borgya A., Gallusser A., et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand. J. Clin. Lab. Invest. Suppl. 230:1999;177-181
29. Schiller N.B. Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommendations of the American Society of Echocardiography. Circulation. 1991:(3 Suppl.):1991;I280-I287
30. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 57:1986;450-458
31. Devereux R.B., Lutas E.M., Casale P.N., et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J. Am. Coll. Cardiol. 4:1984;1222-1230
32. Yuda S., Khoury V., Marwick T.H. Influence of wall stress and left ventricular geometry on the accuracy of dobutamine stress echocardiography. J. Am. Coll. Cardiol. 40:2002;1311-1319
33. Garcia M.J., Thomas J.D., Klein A.L. New Doppler echocardiographic applications for the study of diastolic function. J. Am. Coll. Cardiol. 32:1998;865-875
34. Harrap S.B., Dominiczak A.F., Fraser R., et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation. 93:1996;1148-1154
35. Verdecchia P., Reboldi G., Schillaci G., et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation. 100:1999;1802-1807
36. Greenwood J.P., Scott E.M., Stoker J.B., Mary D.A. Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J. Am. Coll. Cardiol. 38:2001;1711-1717
37. Lubien E., DeMaria A., Krishnaswamy P., et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 105:2002;595-601
38. Galderisi M., Cicala S., Caso P., et al. Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am. J. Cardiol. 15:(90):2002;860-864
39. Tendera M. Ageing and heart failure: the place of ACE inhibitors in heart failure with preserved systolic function. Eur. Heart J. 2:(Suppl. I):2000;I8-I14
40. Zile M.R., Gaasch W.H., Carroll J.D., Feldman M.D., Aurigemma G.P., Schaer G.L., et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation. 104:2001;779-782
41. Hurrell D.G., Nishimura R.A., Ilstrup D.M., Appleton C.P. Utility of preload alteration in assessment of left ventricular filling pressure by Doppler echocardiography: a simultaneous catheterization and Doppler echocardiographic study. J. Am. Coll. Cardiol. 30:1997;459-467
42. McMurray J. The signs and symptoms of heart failure. Ball S.G., Campwell R.W.F., Frances G.S. International handbook of heart failure. 1994;5-12 Euromed Communications Ltd